Pulmonary arterial hypertension: A disease of tethers, SNAREs and SNAPs?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 1, 2007, Pages

  Sehgal, Pravin B ^a   Mukhopadhyay, Somshuvra ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Caveolin 1; Endothelial nitric oxide synthase; Golgi blockade; Intracellular vesicular trafficking; N ethylmaleimide sensitive factor; Nef protein; Nitric oxide; Tethers

Indexed keywords

ANGIOPOIETIN RECEPTOR; BONE MORPHOGENETIC PROTEIN 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; NEF PROTEIN; SNARE PROTEIN;

CELL MEMBRANE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GOLGI COMPLEX; HUMAN; INTRACELLULAR MEMBRANE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, PULMONARY; MODELS, CARDIOVASCULAR; PULMONARY ARTERY; SNARE PROTEINS; VESICULAR TRANSPORT PROTEINS;

EID: 34547137380     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01386.2006     Document Type: Review

References (108)

1. Achcar ROD, Demura Y, Rai PR, Taraseviciene-Stewart L, Kasper M, Voelkel NF, Cool CD. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest 129: 696-705, 2006.
2. Afzelius BA, Schoental R. The ultrastructure of the enlarged hepatocytes induced in rats with a single oral dose of retrorsine, a pyrrolozidine (Senecio) alkaloid. J Ultrastruct Res 20: 328-345, 1967.
3. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, Miyazono K, Li E, Bolch KD. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 287: L1241-L1247, 2004.
4. Bhargava A, Kumar A, Yuan N, Gewitz MH, Mathew R. Monocrotaline induces interleukin-6 mRNA expression in rat lungs. Heart Dis 1: 126-132, 1999.
5. Bogdanovic E, Nguyen VP, Dumont DJ. Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization. J Cell Sci 119: 3551-3560, 2006.
6. Bonifacino JS, Glick BS. The mechanism of vesicle budding and fusion. Cell 116: 153-166, 2004.
7. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Bonnet S, Harmony A, Harry G, Moudgil R, McMurtry MS, Weir EK, Archer SL. An abnormal mitochondrial-hypoxia inducible factor-1α-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 113: 2630-2641, 2006.
8. Burtney A, Rappoport JZ, Bouchet J, Basmaciogullari S, Guatelli J, Simon SM, Benichou S, Benmerah A. Dynamic interaction of HIV-1 Nef with the clathrin-mediated endocytic pathway at the plasma membrane. Traffic 8: 61-76, 2007.
9. Charron AJ, Bacallo R, Wandinger-Ness A. ADPKD: a human disease altering Golgi function and basolateral exocytosis in renal epithelia. Traffic 1: 675-686, 2000.
10. Charron AJ, Nakamura S, Bacallo R, Wandinger-Ness A. Compromised cytoarchitecture and polarized trafficking in autosomal dominant polycystic kidney disease cells. J Cell Biol 149: 111-124, 2000.
11. Chaudhuri R, Lindwasser OW, Smith WJ, Hurley JH, Bonifacino JS. Downregulation of CD4 by human immunodeficiency virus type 1 nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor. J Virol 81: 3877-3890, 2007.
12. Chiu R, Novikov L, Mukherjee S, Shields D. A caspase cleavage fragment of p115 induces fragmentation of the Golgi apparatus and apoptosis. J Cell Biol 159: 637-648, 2002.
13. Choi WS, Khurana A, Mathur R, Viswanathan V, Steele DF, Fedida D. Kv1.5 surface expression is modulated by retrograde trafficking of newly endocytosed channels by the dynein motor. Circ Res 97: 363-371, 2005.
14. Choudhry A, Marks DL, Proctor KM, Gould GW, Pagano RE. Regulation of caveolar endocytosis by syntaxin 6-dependent delivery of membrane components to the cell surface. Nat Cell Biol 8: 317-328, 2006.
15. v 1.5 channel internalization. Circ Res 98: 931-938, 2006.
16. Cool CD, Groshong SD, Oakey J, Voelkel NF. Pulmonary hypertension cellular and molecular mechanisms. Chest 128: 565S-571S, 2005.
17. Cooper AA, Gitler AD, Cashika A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S. α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313: 324-328, 2006.
18. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fisher SG, Barst RJ, Hodge SE, Knowles JA. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67: 737-744, 2000.
19. Dewachter L, Adnot S, Fadel E, Humbert M, Maitre B, Barlier-Mur AM, Simonneau G, Hamon M, Naeije R, Eddahibi S. Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am J Respir Crit Care Med 174: 1025-1033, 2006.
20. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-β receptor signaling and turnover. Nat Cell Biol 5: 410-421, 2003.
21. Donati RJ, Thukral C, Rasenick MM. Chronic treatment of C6 glioma cells with antidepressant drugs results in a redistribution of Gsα. Mol Pharmacol 59: 1426-1432, 2001.
22. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf P, Yaun JX, Deutsch R, Jamieson SW, Thistlethwaite PA. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348: 500-509, 2003.
23. Fagan KA, Fouty BW, Tyler RC, Morris KG Jr, Hepler LK, Sato K, LeCras TD, Abman SH, Weinberger HD, Huang PL, McMurtry IF, Rodman DM. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J Clin Invest 103: 291-299, 1999.
24. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in lungs of patients with pulmonary hypertension. N Engl J Med 333: 214-221, 1995.
25. Gissen P, Johnson CA, Morgan NV, Stapelbroek JM, Forshew T, Cooper WN, McKiernan PJ, Klomp LW, Morris AA, Wraith JE, McClean P, Lynch SA, Thompson RJ, Lo B, Quarrel OW, Di Rocco M, Trembath RC, Mandel H, Wali S, Karet FE, Knisely AS, Houwen RH, Kelly DA, Maher ER. Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat Genet 36: 400-404, 2004.
26. Golemski SM, West J, Tada Y, Fagan KA. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest 128: 572S-573S, 2005.
27. Govers R, Oess S. To NO or not to NO: "where?" is the question. Histol Histopathol 19: 585-605, 2005.
28. Hagen M, Fagan K, Steudel W, Carr M, Kirk K, Rodman DM, West J. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol. First published February 23, 2007; doi:10.1152/ajplung.00197.2006.
29. Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD, Elliot CG, Robbins IM, Olschewski H, McLaughlin V, Gruenig E, Kermeen F, Laitinen T, Halme M, Raisanen-Sokolowski A, Morell NW, Trembath RC. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary hemorrhagic telangiectasia. J Med Genet 40: 865-871, 2003.
30. Hartung A, Bitton-Worms K, Rechtman MM, Wenzel V, Boergerman JH, Hassel S, Henis YI, Knaus P. Different routes of bone morphogenetic protein (BMP) receptor endocytosis influence BMP signaling. Mol Cell Biol 26: 7791-7805, 2006.
31. Heath D, Smith P, Gosney J, Mulcahy D, Fox K, Yacoub M, Harris P. The pathology of early and late stages of primary pulmonary hypertension. Br Heart J 58: 204-213, 1987.
32. Hironaka E, Hongo M, Sakai A, Mawatari E, Terasawa F, Okumura N, Yamazaki A, Ushiyama Y, Yazaki Y, Kinoshita O. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 60: 692-699, 2003.
33. Hong W. SNAREs and traffic. Biochim Biophys Acta 1744: 493-517, 2005.
34. Hongo M, Mawatari E, Sakai A, Ruan Z, Koizumi T, Terasawa F, Yazaki Y, Kinoshita O, Ikeda U, Shibamoto T. Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats. J Cardiovasc Pharmacol 46: 452-458. 2005.
35. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir KE, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S, 2004.
36. Itoh F, Divecha N, Brocks L, Oomen L, Janssen H, Calafat J, Itoh S, Dijke PP. The FYVE domain in Smad anchor for receptor activation (SARA) is sufficient for localization of SARA in early endosomes and regulates TGF-β/Smad signalling. Genes Cells 7: 321-331, 2002.
37. Iwakiri Y, Satoh A, Chatterjee S, Toomre DK, Chalouni CM, Fulton D, Grozmann RJ, Shah VH, Sessa WC. Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proc Natl Acad Sci USA 103: 19777-19782, 2006.
38. Jaenke RS, Alexander AF. Fine structural alterations of bovine peripheral pulmonary arteries in hypoxia-induced hypertension. Am J Pathol 73: 377-398, 1973.
39. Jahn R, Scheller RH. SNAREs - engines for membrane fusion. Nat Rev Mol Cell Biol 7: 631-643, 2006.
40. Jasmin JF, Mercier I, Dupuis J, Tanowitz HB, Lisanti MP. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 114: 912-920, 2006.
41. Kanno S, Wu YJ, Lee PC, Billiar TR, Ho C. Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 104: 945-950, 2001.
42. Kido M, Du L, Sullivan CC, Deutsch R, Jamieson SW, Thistlethwaite PA. Gene transfer of a Tie2 receptor antagonist prevents pulmonary hypertension in rodents. J Thorac Cardiovasc Surg 129: 268-276, 2005.
43. King AP, Smith P, Heath D. Ultrastructure of rat pulmonary arterioles after neonatal exposure to hypoxia and subsequent relief and treatment with monocrotaline. J Pathol 177: 71-81, 1995.
44. Koptides M, Mean R, Demetriou K, Pierides A, Deltas CC. Genetic evidence for a trans-heterozygous model for cystogenesis in autosomal dominant polycystic kidney disease. Hum Mol Genet 9: 447-452, 2000.
45. Kugathasan L, Dutly AE, Zhao YD, Deng Y, Robb MJ, Keshavjee S, Stewart DJ. Role of angiopoetin-1 in experimental and human pulmonary arterial hypertension. Chest 128: 633S-642S, 2005.
46. Lane KB, Machado RD, Pauciulo MW, Thompson JR, Phillips JAIII, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2 encoding a TGF-β receptor, cause familial pulmonary hypertension. Nat Genet 26: 81-84, 2000.
47. Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 161: 1357-1369, 2002.
48. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudrakanchana N, Southwood M, James V, Trembath RC, Morrell NW. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98: 818-827, 2006.
49. Machado RD, James V, Southwood M, Harrison RE, Atkinson C, Stewart S, Morrell NW, Trembath RC, Aldred MA. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 111: 607-613, 2005.
50. Madrid R, Janvier K, Hitchin D, Day J, Coleman S, Noviello C, Bouchet J, Benmerah A, Guatelli J, Benichou S. Nef-induced alteration of the early/recycling endosomal compartment correlates with enhancement of HIV-1 infectivity. J Biol Chem 280: 5032-5044, 2005.
51. Marecki JC, Cool CD, Parr JE, Beckley VE, Luciw PA, Tarantal AF, Carville A, Shannon RP, Cota-Gomez A, Tuder RM, Voelkel NF, Flores SC. HIV Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 174: 437-445, 2006.
52. Mathew R, Huang J, Shah M, Patel K, Gewitz M, Sehgal PB. Disruption of endothelial-cell caveolin-1α/raft scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 110: 1499-1506, 2004.
53. Mathew R, Yuan N, Rosenfeld L, Gewitz MH, Kumar A. Effects of monocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs. Heart Dis 4: 152-158, 2002.
54. Matsushita K, Morrell CN, Cambein B, Yang SX, Yamakuchi M, Bao C, Hara MR, Quick RA, Cao W, O'Rourke B, Lowenstein JM, Pevsner J, Wagner DD, Lowestein CJ. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethlymaleimide sensitive factor. Cell 115: 139-150, 2003.
55. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 114: 1417-1431, 2006.
56. McMurtry MS, Moudgil R, Hashimoto K, Bonnet S, Michelakis ED, Archer SL. Overexpression of human bone morphogenetic protein receptor II does not ameliorate monocrotaline pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 292: L872-L878, 2007.
57. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112: 423-431, 2005.
58. Meyrick B, Reid L. Hypoxia-induced structural changes in the media and adventitia of the rat hilar pulmonary artery and their regression. Am J Pathol 100: 151-178, 1980.
59. Meyrick B, Reid L. The effect of continued hypoxia on rat pulmonary arterial circulation. Lab Invest 38: 188-200, 1978.
60. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Mougdil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 105: 244-250, 2002.
61. Mizumoto H, Hata D, Yamamoto K, Shirakawa R, Kumakura A, Shiota M, Yokoyama A, Matsubara H, Kobayashi M, Nishiomori R, Adachi S, Nakahata T, Kita T, Horiuchi H, Yasukawa M, Ishii E. Familial hemophagocytic lymphohistiocytosis with the MUNC13-4 mutation: a case report. Eur J Pediatr 165: 384-388, 2006.
62. Morrell NW. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? Proc Am Thorac Soc 3: 680-686, 2006.
63. Mukhopadhyay S, Sehgal PB. Discordant regulatory changes in monocrotaline-induced megalocytosis of lung arterial endothelial and alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 290: L1216-L1226, 2006.
64. Mukhopadhyay S, Shah M, Patel K, Sehgal PB. Monocrotaline pyrrole-induced megalocytosis of lung and breast epithelial cells: disruption of plasma membrane and Golgi dynamics and an enhanced unfolded protein response. Toxicol Appl Pharmacol 211: 209-220, 2006.
65. Mukhopadhyay S, Xu F, Sehgal PB. Aberrant cytoplasmic sequestration of eNOS in endothelial cells after monocrotaline, hypoxia and senescence: subcellular eNOS localization and live-cell caveolar and cytoplasmic NO imaging studies. Am J Physiol Heart Circ Physiol 292: H1373-H1389, 2007.
66. Murata T, Sato K, Hori M, Ozaki H, Karaki H. Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem 277: 44085-44092, 2002.
67. Nakazawa H, Hori M, Ozaki H, Karaki H. Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats. Br J Pharmacol 128: 1098-1104, 1999.
68. Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JGN, Kao PN, Knowles JA, Loyd JE, McGoon MD, Morse JH, Nichols WC, Rabinovitch M, Rodman DM, Stevens T, Tuder RM, Voelkel NF, Gail DB. Pulmonary arterial hypertension: future directions. Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 109: 2947-2952, 2004.
69. Nishihara A, Watabe T, Imamura T, Miyazono K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell 13: 3055-3063, 2002.
70. Nozawa K, Fritzler MJ, von Muhlen CA, Chan EK. Giantin is the major Golgi autoantigen in human anti-Golgi complex sera. Arthritis Res Ther 6: R95-R102, 2003.
71. Panopoulou E, Gillooly DJ, Wrana JL, Zerial M, Stenmark H, Murphy C, Fotsis T. Early endosome regulation of Smad-dependent signaling in endothelial cells. J Biol Chem 277: 18046-18052, 2002.
72. Persu A, Duyme M, Pirson Y, Lens XM, Messiaen T, Breuning MH, Chauveau D, Levy M, Grunfeld JP, Devuyst O. Comparison between siblings and twins supports a role for modifier genes in ADPKD. Kidney Int 66: 2132-2136, 2004.
73. Predescu SA, Predescu DN, Shimizu K, Klien IK, Malik AB. Cholesterol-dependent syntaxin-4 and SNAP-23 clustering regulates caveolar fusion with the endothelial plasma membrane. J Biol Chem 280: 37130-37138, 2005.
74. Quinlan TR, Dechun L, Laubach VE, Shesley EG, Zhou N, Johns R. eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 279: L641-L650, 2000.
75. Rabinovitch M. Cellular and molecular pathobiology of pulmonary hypertension conference summary. Chest 128: 642-646, 2005.
76. Resta TC, Gonzales RJ, Dail WG, Sanders TC, Walker BR. Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol Heart Circ Physiol 272: H806-H813, 1997.
77. Reynolds AN, Xia W, Holmes MD, Hodge SJ, Danilov S, Curiel DT, Morrell NW, Reynolds PN. Bone morphogenetic protein type 2 receptor (BMPR2) gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 292: L1182-L1192, 2007.
78. Roeth JF, Williams M, Kasper MR, Filzen TM, Collins KL. HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J Cell Biol 167: 903-913, 2004.
79. Rosen EM, Liu D, Setter E, Bhargava M, Goldberg ID. Interleukin-6 stimulates motility of vascular endothelium. In: Cell Motility Factors, edited by Goldberg ID, Rosen EM. Basel, Switzerland: Birkhauser-Verlag, 1991, p. 194-205.
80. Rudrakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath RC, Morrell NW. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 11: 1517-1525, 2002.
81. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 361: 1533-1544, 2003.
82. Sahashi K, Ibi T, Ohno K, Sahashi k Nakao N, Kondo H. Progressive myopathy with circulating autoantibody against giantin in the Golgi apparatus. Neurology 62: 1891-1893, 2004.
83. Sato K, Roadman DM, McMurtry IF. Hypoxia inhibits increased ETB receptor-mediated NO synthesis in hypertensive rat lungs. Am J Physiol Lung Cell Mol Physiol 276: L571-L581, 1999.
84. Schermuly RT, Dony E, Ghofrai HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821, 2005.
85. Sehgal PB, Mukhopadhyay S, Xu F, Patel K, Shah M. Dysfunction of Golgi tethers, SNAREs and SNAPs in monocrotaline-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. First published March 2, 2007; doi:10.1152/ajplung.00463.2006.
86. Sehgal PB, Tamm I. Interleukin-6 enhances motility of breast carcinoma cells. In: Cell Motility Factors, edited by Goldberg ID, Rosen EM. Basel, Switzerland: Birkhauser-Verlag, 1991, p. 178-193.
87. Shah M, Patel K, Mukhopadhyay S, Xu F, Guo G, Sehgal PB. Membrane associated STAT3 and PY-STAT3 in the cytoplasm. J Biol Chem 281: 7302-7308, 2006.
88. Shah M, Patel K, Sehgal PB. Monocrotaline induced endothelial cell megalocytosis involves a Golgi blockade mechanism. Am J Physiol Cell Physiol 288: C850-C862, 2005.
89. Smith P, Heath D. Electron microscopy of the plexiform lesion. Thorax 34: 177-186, 1979.
90. Smith P, Heath D, Yacoub M, Madden B, Caslin A, Gosney J. The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol 160: 111-121, 1990.
91. Song Y, Jones JE, Beppu H, Keaney JF, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 112: 553-562, 2005.
92. Stenmark KR, McMurtry IF. Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal? Circ Res 97: 95-98, 2005.
93. Stow JL, Manderson AP, Murray RZ. SNAREing immunity: the role of SNAREs in the immune system. Nat Rev Immunol 6: 919-929, 2006.
94. Sullivan CC, Du L, Chu D, Cho AJ, Kido M, Wolf PL, Jamieson SW, Thistlethwaite PA. Induction of pulmonary hypertension by an angiopoietin 1/Tie2/serotonin pathway. Proc Natl Acad Sci USA 100: 12331-12336, 2003.
95. Sztul E, Lupashin V. Role of tethering factors in secretory membrane traffic. Am J Physiol Cell Physiol 290: C11-C26, 2006.
96. Tani K, Shibata M, Kawase K, Kawashima H, Hatsuzawa K, Nagahama M, Tagaya M. Mapping the functional domains of γ-SNAP. J Biol Chem 278: 13531-13538, 2003.
97. Taraseviciene-Stewart L, Scerbavicius R, Choe HH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 291: L668-L676, 2006.
98. Toki C, Fujiwara T, Sohda M, Hong HS, Misumi Y, Ikehara Y. Identification and characterization of rat 364-kDa Golgi-associated protein recognized by autoantibodies from a patient with rheumatoid arthritis. Cell Struct Funct 22: 565-577, 1997.
99. Tsukazaki T, Chaing TA, Davison AF, Attisano L, Wrana JL. SARA a FYVE domain protein that recruits Smad2 to the TGFβ receptor. Cell 95: 779-791, 1998.
100. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kashahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM, Voelkel NF. Expression of angiogenesis-related molecules in plexiform lesions of severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 195: 367-394, 2001.
101. Tyler RC, Muramatsu M, Abman SH, Stelzner TJ, Rodman DM, Bloch KD, McMurtry IF. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 276: L297-L303, 1999.
102. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 114: 225-230, 1998.
103. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, Rodman DM. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 94:1109-1114, 2004.
104. Yao JS, Zhai W, Fan Y, Lawton MT, Barbaro NM, Young WL, Yang GY. Interleukin-6 upregulates expression of KDR and stimulates proliferation of human cerebrovascular smooth muscle cells. J Cereb Blood Flow Metab 27: 510-520, 2007.
105. Yoon TY, Okumus B, Zhang F, Shin YK, Ha T. Multiple intermediates in SNARE-induced membrane fusion. Proc Natl Acad Sci USA 103: 19731-19736, 2006.
106. Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 111: 534-538, 2005.
107. Zhao YD, Campbell AI, Robb M, Ng D, Stewart DJ. Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ Res 92: 984-991, 2003.
108. Zhou YY, Liy Y, Stan RV, Fan L, Gu Y, Chu PH, Peterson K, Ross J Jr, Chien KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 99: 11375-11380, 2002.